MarketCap
Facebook
X
TelegramAnnual report 2025
added 04-18-2026
Legend Biotech Corporation Operating Cash Flow 2011-2026 | LEGN
Annual Operating Cash Flow Legend Biotech Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | -198 M | -223 M | -83.1 M | 308 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 308 M | -223 M | -49.2 M |
Operating Cash Flow of other stocks in the Biotechnology industry
| Issuer | Operating Cash Flow | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-481 M | - | 2.43 % | $ 254 M |  Germany |
 |
AgeX Therapeutics
AGE
|
-18 M | - | -10.17 % | $ 12.2 K |  USA |
 |
I-Mab
IMAB
|
-1.3 B | - | - | $ 866 M |  China |
 |
Midatech Pharma plc
MTP
|
-6.01 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Esperion Therapeutics
ESPR
|
-13.1 M | $ 3.13 | 0.55 % | $ 651 M | USA |
 |
Exelixis
EXEL
|
884 M | $ 46.48 | 4.64 % | $ 12.6 B | USA |
 |
Fortress Biotech
FBIO
|
-65.8 M | $ 2.5 | 1.63 % | $ 69.8 M | USA |
 |
Biophytis SA
BPTS
|
-23.8 M | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
99.9 M | - | 2.54 % | $ 160 B | France |
 |
Athira Pharma
ATHA
|
-45.7 M | - | - | $ 269 M | USA |
 |
Galapagos NV
GLPG
|
-504 M | $ 28.79 | 1.41 % | $ 2.69 B |  Belgium |
 |
Genmab A/S
GMAB
|
1.33 B | $ 27.79 | 0.92 % | $ 17.1 B |  Danmark |
 |
Genprex
GNPX
|
-15.3 M | $ 0.9 | 1.12 % | $ 839 K | USA |
 |
Grifols, S.A.
GRFS
|
597 M | $ 8.33 | 0.73 % | $ 6.83 B |  Spain |
 |
InflaRx N.V.
IFRX
|
-39.9 M | $ 2.51 | 27.51 % | $ 152 M | Germany |
 |
Immuron Limited
IMRN
|
-3.15 M | $ 0.8 | 1.39 % | $ 6.7 M |  Australia |
 |
Ionis Pharmaceuticals
IONS
|
-269 M | $ 76.27 | 1.36 % | $ 12.2 B | USA |
 |
BioNTech SE
BNTX
|
890 M | $ 95.08 | -0.44 % | $ 27.2 B | Germany |
 |
Kamada Ltd.
KMDA
|
-8.82 M | $ 8.28 | 0.85 % | $ 260 M |  Israel |
 |
Checkmate Pharmaceuticals
CMPI
|
-53.7 M | - | - | $ 231 M | USA |
 |
Kymera Therapeutics
KYMR
|
-233 M | $ 85.67 | 3.58 % | $ 7.24 B | USA |
 |
Kazia Therapeutics Limited
KZIA
|
-22.8 M | $ 13.28 | -1.26 % | $ 1.76 B | Australia |
 |
INmune Bio
INMB
|
-22.6 M | $ 1.54 | - | $ 38.1 M | USA |
 |
Ligand Pharmaceuticals Incorporated
LGND
|
97 M | $ 232.25 | -0.02 % | $ 4.25 B | USA |
 |
Liquidia Corporation
LQDA
|
-35.7 M | $ 41.83 | 4.24 % | $ 3.6 B | USA |
 |
ACADIA Pharmaceuticals
ACAD
|
158 M | $ 22.89 | 2.42 % | $ 3.79 B | USA |
 |
Mirum Pharmaceuticals
MIRM
|
55.8 M | $ 108.2 | 2.26 % | $ 5.43 B | USA |
 |
Advaxis
ADXS
|
-29.5 M | - | -9.65 % | $ 45.9 M | USA |
 |
MannKind Corporation
MNKD
|
18.3 M | $ 3.84 | 34.27 % | $ 1.17 B | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-8.95 M | $ 3.51 | 0.29 % | $ 5.78 M | Israel |
 |
Aeterna Zentaris
AEZS
|
-8.58 M | - | 5.93 % | $ 314 M |  Canada |
 |
Aeglea BioTherapeutics
AGLE
|
-169 M | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
-733 M | - | - | $ 867 M | Germany |
 |
Applied Genetic Technologies Corporation
AGTC
|
-65.7 M | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
22.7 M | - | 1.93 % | $ 17.4 M | USA |
 |
Akero Therapeutics
AKRO
|
-230 M | - | - | $ 3.67 B | USA |
 |
Aptose Biosciences
APTO
|
-22 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
-59.7 M | - | -39.0 % | $ 4.57 M | USA |
 |
Akouos
AKUS
|
-63.7 M | - | 0.23 % | $ 488 M | USA |
 |
Albireo Pharma
ALBO
|
-108 M | - | -0.23 % | $ 916 M | USA |
 |
Allakos
ALLK
|
-116 M | - | - | $ 28.6 M | USA |
 |
AlloVir
ALVR
|
-38.4 M | - | 4.14 % | $ 49.1 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
-5.62 M | $ 23.68 | 1.09 % | $ 3.01 B | USA |
 |
Nanobiotix S.A.
NBTX
|
-29.9 M | $ 41.17 | 18.39 % | $ 286 B | France |
 |
Allena Pharmaceuticals
ALNA
|
-45.7 M | - | 3.16 % | $ 1.9 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-8.56 M | - | -11.43 % | $ 502 K | USA |
 |
Applied Molecular Transport
AMTI
|
-93.9 M | - | - | $ 10.1 M | USA |